Entera Bio to Present at 23rd Annual HC Wainwright Global Investment Conference



BOSTON and JERUSALEM, August 23, 2021 (GLOBE NEWSWIRE) – Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral large molecule therapies, today announced that the company’s CEO, Spiros Jamas, will present at the HC Wainwright 23rd Annual Global Investment Conference on Monday September 13, 2021 at 3:30 p.m. ET at the Lotte New York Palace Hotel. The hybrid in-person and virtual conference will take place September 13-15, 2021. In addition to the presentation, management will host one-on-one meetings with investors. For more information about the conference or to register, visit: DSS Events.

About Entera Bio

Entera is a leader in the development of orally administered large molecule therapies for use in areas of high unmet medical needs, where adoption of injectable therapies is limited due to concerns of cost, convenience and compliance for patients. The company’s proprietary oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate absorption of large molecules and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are under clinical development. The Company recently completed the Phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

Forward-looking statements

Various statements contained in this press release are “forward-looking statements” under securities laws. Words such as, but not limited to, “anticipate”, “believe”, “power”, “could”, “expect”, “estimate”, “conceive”, “objective”, “have the goal”. ‘intention of’, ‘power’, ” could ‘,’ objective ‘,’ plan ‘,’ plan ‘,’ project ‘,’ target ‘,’ likely ‘,’ should ‘,’ will ‘and’ should ‘, or the negative of such terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based on current expectations which involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be interpreted as a guarantee of future performance or results and may not be precise indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, but are not limited to: changes in our interpretation of the full 3-month biomarker data from the Phase 2 clinical trial recently completed EB613, the schedule of data reads from the recently completed EB613 Phase 2 clinical trial, the full results of the EB613 Phase 2 clinical trial, and our analysis of these comprehensive results, the FDA’s interpretation and review of our results and analysis of our Phase 2 trial of EB613, unexpected changes in our preclinical development and ongoing and planned clinical trials, timing and ability to perform regulatory filings and obtaining and maintaining regulatory approvals for our product candidates; the impact of COVID-19 on Entera’s business operations; the potential disruption and delay of manufacturing supply chains, the loss of available labor resources, either by Entera or its collaboration and lab partners, due to travel restrictions, layoffs or forced closures or reassignment of hospitals; impacts on research and development or clinical activities that Entera is contractually obligated to provide, such as those under Entera’s agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are shut down for extended periods of time, choose to allocate resources to the review of COVID-19-related drugs or believe the amount of Phase 2 clinical data collected is insufficient to initiate a phase 3 trial, or a significant deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of data from the phase 2 clinical trial of EB613 in patients with osteoporosis; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the recently completed phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera’s other product candidates, including any possible market expansion if an orally administered option is available in addition to an injectable formulation; the scope, progress and costs of the development of Entera’s product candidates, including EB612 and GLP-2; Entera’s dependence on third parties to conduct its clinical trials; Entera’s expectations regarding licensing, business transactions and strategic collaborations; the operation of Entera as a development stage company with limited operating history; the ability of Entera to continue operating in the absence of access to sources of liquidity; Entera’s expectations regarding its expenses, income, liquidity, liquidity and financial condition; Entera’s ability to raise additional capital; Entera’s interpretation of FDA’s comments and advice and the impact that such advice may have on its clinical development plans; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq minimum listing standards and other matters related to meeting the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors described in the “Special Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s annual and current documents. which are filed with the SEC and available free of charge on the SEC’s website at http://www.sec.gov. Additional factors may be set out in sections of Entera’s annual report on Form 20-F for the fiscal year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and In Entera’s annual report on Form 20-F and current reports on Form 6-K and other documents filed with the SEC, other unknown or unforeseeable factors could also affect Entera’s results. There can be no assurance that the actual results or developments anticipated by Entera will be achieved or, even if substantially achieved, that they will have the consequences or effects expected on Entera. Therefore, no assurance can be given that the results set forth in these forward-looking statements and estimates will be achieved.

All written and oral forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to place undue reliance on forward-looking statements made by Entera or made on its behalf. The information in this press release is provided only as of the date of this press release, and Entera assumes no obligation, and specifically disclaims any obligation, to publicly update or revise any forward-looking statement, whether thereafter. new information, future events or otherwise.

CONTACT: Contact: Spiros Jamas, CEO Tel: +001 617-362-3579 spiros@enterabio.com



Leave A Reply